Lincoln Pharmaceuticals Limited (NSE:LINCOLN)
India
· Delayed Price · Currency is INR 550.85
-54.70 (-9.03%)
May 22, 2025, 3:30 PM IST
Lincoln Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Operating Revenue | 6,232 | 5,805 | 5,103 | 4,721 | 4,242 | Upgrade
|
| Other Revenue | 224.77 | - | - | - | - | Upgrade
|
| Revenue | 6,457 | 5,805 | 5,103 | 4,721 | 4,242 | Upgrade
|
| Revenue Growth (YoY) | 11.22% | 13.76% | 8.09% | 11.30% | 9.75% | Upgrade
|
| Cost of Revenue | 2,913 | 2,825 | 2,457 | 2,219 | 2,014 | Upgrade
|
| Gross Profit | 3,544 | 2,981 | 2,646 | 2,502 | 2,228 | Upgrade
|
| Selling, General & Admin | 1,125 | 1,074 | 981.38 | 845.1 | 756.63 | Upgrade
|
| Other Operating Expenses | 1,180 | 904.25 | 767.12 | 692 | 597.41 | Upgrade
|
| Operating Expenses | 2,433 | 2,085 | 1,840 | 1,625 | 1,430 | Upgrade
|
| Operating Income | 1,111 | 895.83 | 805.47 | 876.98 | 798.01 | Upgrade
|
| Interest Expense | -18.83 | -9.46 | -16.38 | -9.2 | -12.02 | Upgrade
|
| Interest & Investment Income | - | 70.28 | 61.71 | 50.28 | 22.65 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 46.1 | 109.14 | 11.12 | 4.26 | Upgrade
|
| Other Non Operating Income (Expenses) | - | -5.19 | -3.92 | -4.6 | 1.63 | Upgrade
|
| EBT Excluding Unusual Items | 1,092 | 997.56 | 956.02 | 924.58 | 814.53 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 227.85 | 51.35 | 36.12 | 24.5 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -2.98 | -2.56 | -1.31 | -1.82 | Upgrade
|
| Pretax Income | 1,092 | 1,222 | 1,005 | 959.39 | 837.21 | Upgrade
|
| Income Tax Expense | 268.42 | 289.38 | 275.81 | 265.84 | 214.71 | Upgrade
|
| Earnings From Continuing Operations | 823.46 | 933.05 | 728.99 | 693.55 | 622.5 | Upgrade
|
| Net Income | 823.46 | 933.05 | 728.99 | 693.55 | 622.5 | Upgrade
|
| Net Income to Common | 823.46 | 933.05 | 728.99 | 693.55 | 622.5 | Upgrade
|
| Net Income Growth | -11.74% | 27.99% | 5.11% | 11.41% | 21.02% | Upgrade
|
| Shares Outstanding (Basic) | 20 | 20 | 20 | 20 | 20 | Upgrade
|
| Shares Outstanding (Diluted) | 20 | 20 | 20 | 20 | 20 | Upgrade
|
| Shares Change (YoY) | 0.01% | - | - | - | 0.15% | Upgrade
|
| EPS (Basic) | 41.11 | 46.58 | 36.40 | 34.63 | 31.08 | Upgrade
|
| EPS (Diluted) | 41.11 | 46.58 | 36.40 | 34.63 | 31.08 | Upgrade
|
| EPS Growth | -11.74% | 27.98% | 5.11% | 11.41% | 20.84% | Upgrade
|
| Free Cash Flow | 739.86 | 237.41 | 250.03 | 306.07 | 605.19 | Upgrade
|
| Free Cash Flow Per Share | 36.94 | 11.85 | 12.48 | 15.28 | 30.21 | Upgrade
|
| Dividend Per Share | - | 1.800 | 1.500 | 1.500 | 1.500 | Upgrade
|
| Dividend Growth | - | 20.00% | - | - | - | Upgrade
|
| Gross Margin | 54.88% | 51.34% | 51.84% | 52.99% | 52.52% | Upgrade
|
| Operating Margin | 17.20% | 15.43% | 15.78% | 18.57% | 18.81% | Upgrade
|
| Profit Margin | 12.75% | 16.07% | 14.29% | 14.69% | 14.67% | Upgrade
|
| Free Cash Flow Margin | 11.46% | 4.09% | 4.90% | 6.48% | 14.27% | Upgrade
|
| EBITDA | 1,240 | 1,001 | 895.8 | 956.29 | 872.01 | Upgrade
|
| EBITDA Margin | 19.20% | 17.24% | 17.55% | 20.26% | 20.56% | Upgrade
|
| D&A For EBITDA | 128.99 | 104.97 | 90.33 | 79.31 | 74 | Upgrade
|
| EBIT | 1,111 | 895.83 | 805.47 | 876.98 | 798.01 | Upgrade
|
| EBIT Margin | 17.20% | 15.43% | 15.78% | 18.57% | 18.81% | Upgrade
|
| Effective Tax Rate | 24.58% | 23.67% | 27.45% | 27.71% | 25.65% | Upgrade
|
| Revenue as Reported | 6,457 | 6,150 | 5,328 | 4,821 | 4,298 | Upgrade
|
| Advertising Expenses | - | 10.34 | 11.57 | 0.6 | 0.47 | Upgrade
|
Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.